Patent · US Active

Method of adjuvant cancer treatment

US10869869B2 · kind B2 · utility

8Cited by
0References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 28, 2019
Grant dateDec 22, 2020
Priority date
Expiry dateOct 28, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.